Aurinia Pharmaceuticals(AUPH)

Search documents
Aurinia Pharmaceuticals(AUPH) - 2024 Q2 - Quarterly Results
2024-08-01 10:03
Exhibit 99.1 AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS • Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively • Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 • Co ...
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
ZACKS· 2024-07-12 09:41
Aurinia Pharmaceuticals (AUPH) shares ended the last trading session 6.6% higher at $5.86. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.9% gain over the past four weeks.The rise in share price was attributable to positive investor expectations for Lupkynis, the company’s sole marketed drug which is approved for treatment of adults with active lupus nephritis (LN). Sales of the drug are being driven predominant ...
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
ZACKS· 2024-06-17 09:50
Aurinia Pharmaceuticals (AUPH) shares rallied 5.6% in the last trading session to close at $5.65. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks.The sudden soar in the stock price of the company is likely due to the positive momentum built around its pipeline. Aurinia's sole-marketed product, Lupkynis, is approved in the United States for the treatment of lupus nephritis. T ...
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Zacks Investment Research· 2024-05-07 15:01
Aurinia Pharmaceuticals (AUPH) closed the last trading session at $5.16, gaining 3.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.14 indicates a 96.5% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $3.13. While the lowest estimate of $6 indicates a 16.3% increase from the current price level, the most optimistic anal ...
Aurinia Pharmaceuticals(AUPH) - 2024 Q1 - Earnings Call Transcript
2024-05-02 16:03
Financial Data and Key Metrics Changes - Aurinia achieved total net revenue of $50.3 million in Q1 2024, representing a growth of approximately 46% year-over-year [9][19] - Net product revenue was $48.1 million, reflecting a significant growth of approximately 40% [9][19] - The company expects to achieve net product revenue guidance of approximately $200 million to $220 million for the year [9][10] - Operating expenses are projected to be reduced by $50 million to $55 million over the next 12 months, with total annualized operating expenses expected to be in the range of $185 million to $195 million [10][19] Business Line Data and Key Metrics Changes - The company added 448 patient start forms (PSFs) and approximately 148 new patients in Q1 2024, totaling approximately 596 PSFs compared to 466 PSFs in the prior year [11] - As of March 31, 2024, there were approximately 2,178 patients on loop kinase therapy, an increase of approximately 26% from 1,731 patients a year earlier [11][12] - Net realizable revenue per patient for LUPKYNIS is now estimated to be in the range of $70,000 to $75,000 annually, higher than the initial guidance of $65,000 [12][60] Market Data and Key Metrics Changes - The company is seeing continued revenue from Otsuka's launch activities in Europe and is working on expanding access to LUPKYNIS in Japan, with a regulatory response expected in the second half of 2024 [17] - The "Know the Signs" campaign aims to increase awareness among rheumatologists about lupus nephritis and the need for better screening practices [16] Company Strategy and Development Direction - The company is focused on driving loop kinase revenues and improving commercial execution while restructuring to achieve cash flow positivity [8][10] - The FDA has approved a label update for LUPKYNIS, which now includes long-term data, enhancing the drug's market position [14][15] - The company is exploring alternative approaches for AUR 200 after ceasing development on AUR 300, indicating a strategic pivot in its pipeline [9][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in Q2 2024, ahead of prior projections [10] - The management highlighted the importance of improving physician understanding of lupus nephritis treatment guidelines to drive long-term growth [16][55] - The company anticipates that the updated label will enhance persistency and length of therapy for patients [29][55] Other Important Information - The company reduced its employee headcount by approximately 25% in Q1 2024 as part of its restructuring efforts [10] - As of March 31, 2024, Aurinia had cash and cash equivalents of $320.1 million, down from $350.7 million at the end of 2023 [24] Q&A Session Summary Question: Implications of the updated label on conversion rates - Management believes the label update will enhance persistency and ensure the drug is utilized according to treatment guidelines, rather than significantly impacting conversion rates [29] Question: Trends in patient start forms and April performance - Management noted that PSFs in April 2024 were consistent with April 2023, with a slight year-over-year improvement driven by restarts and hospital patients [31] Question: Importance of formulary purchases in the hospital channel - Management emphasized that while PSFs are important, restarts and hospital business are emerging as significant growth areas [35] Question: Revenue guidance and seasonal expectations - Management indicated that the low end of revenue guidance would require a significant decline in summer, while strong performance in Q2 could lead to an upper range outcome [38][39] Question: Development timelines for AUR 200 - The IND for AUR 200 has been approved, and the company is moving into SAD/MAD studies [59] Question: Updated pricing expectations for LUPKYNIS - The increase in pricing expectations is attributed to improved persistency rates and small price increases over time [60]
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-05-02 12:11
分组1 - Aurinia Pharmaceuticals reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.18 per share a year ago, resulting in an earnings surprise of 82.35% [1] - The company generated revenues of $50.3 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 8.65%, and showing a year-over-year increase from $34.41 million [1] - Over the last four quarters, Aurinia has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [1] 分组2 - Aurinia shares have declined approximately 42.2% since the beginning of the year, contrasting with the S&P 500's gain of 5.2% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $54.19 million, and for the current fiscal year, it is -$0.06 on revenues of $225.59 million [4] - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [4]
Aurinia Pharmaceuticals(AUPH) - 2024 Q1 - Quarterly Report
2024-05-02 10:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|---------------------- ...
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
Businesswire· 2024-02-29 13:30
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current Program. Aurinia announced on February 15th that its Board of Directors (the “Board”) had approved a ...
Aurinia Pharmaceuticals(AUPH) - 2023 Q4 - Earnings Call Transcript
2024-02-15 15:10
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Conference Call February 15, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Farzin Haque - Jefferies Stacy Ku - TD Cowen Ed Arce - HC Wainwright Operator Greetings. Welcome to Aurinia Pharmaceuticals' Full Year 2023 Earnings Call. At this time, all participants are in a listen-onl ...
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-02-15 13:26
Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.17 per share when it actually produced a loss of $0.09, delivering a surprise of 47.06%.Over the last four quarters, th ...